{"_buckets": {"deposit": "8201224b-0409-4321-90fd-b7a3ba03ad34"}, "_deposit": {"id": "20122", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "20122"}, "status": "published"}, "_oai": {"id": "oai:niigata-u.repo.nii.ac.jp:00020122", "sets": ["456", "1161"]}, "item_7_alternative_title_1": {"attribute_name": "その他のタイトル", "attribute_value_mlt": [{"subitem_alternative_title": "Urinary Excretion of Guanidinoacetic Acid in Cisplatin Nephropathy"}]}, "item_7_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "1993-06", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "6", "bibliographicPageEnd": "532", "bibliographicPageStart": "523", "bibliographicVolumeNumber": "107", "bibliographic_titles": [{"bibliographic_title": "新潟医学会雑誌"}, {"bibliographic_title": "新潟医学会雑誌", "bibliographic_titleLang": "en"}]}]}, "item_7_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "This study was attempted to evaluate the nephrotoxicity of Cisplatin (CDDP) in 10 lung cancer patients by urinary excretion of guanidinoacetic acid (GAA) , which was produced mainly in the renal proximal tubules by transamidination of glycine from arginine. The urine concentration of N-acetyl-β-glucosaminidase (NAG) and β_2-microglobulin (BMG) was also compared with that of GAA. The urine level of GAA, NAG, and BMG (U-GAA, U-NAG, U-BMG) was measured by high performance liquid chromatography (HPLC), enzyme immunoassay, and latex agglutination method respectively. The serum creatinine level had a significant negative correlation with urinary excretion of GAA (r=-0.35, p\u003c0.05). After administration of CDDP, U-GAA decreased significantly on day 0, 3, 7, 10 and 14. Similarly, U-NAG increased on day 3, 7, and U-BMG on day 0, 1. However, these changes were less prominent than that of U-GAA. The further studies of long-term treated 3 cases revealed that U-GAA was a more sensitive marker than U-NAG or U-BMG in CDDP nephropathy. These findings suggest that U-GAA is extremely useful for early detection of CDDP nephropathy.", "subitem_description_type": "Abstract"}]}, "item_7_full_name_3": {"attribute_name": "著者別名", "attribute_value_mlt": [{"nameIdentifiers": [{"nameIdentifier": "124474", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "Tasaki, Kazuyuki"}]}]}, "item_7_publisher_7": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "新潟医学会"}]}, "item_7_select_19": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_7_source_id_11": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AN00182415", "subitem_source_identifier_type": "NCID"}]}, "item_7_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "00290440", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "田崎, 和之"}], "nameIdentifiers": [{"nameIdentifier": "124473", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-08-16"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "107(6)_523-532.pdf", "filesize": [{"value": "1.8 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 1800000.0, "url": {"label": "107(6)_523-532.pdf", "url": "https://niigata-u.repo.nii.ac.jp/record/20122/files/107(6)_523-532.pdf"}, "version_id": "01565700-74c3-4029-a97e-1ae0e1436ee0"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "GAA", "subitem_subject_scheme": "Other"}, {"subitem_subject": "NAG", "subitem_subject_scheme": "Other"}, {"subitem_subject": "BMG", "subitem_subject_scheme": "Other"}, {"subitem_subject": "CDDP nephropathy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "グアニジニノ酢酸", "subitem_subject_scheme": "Other"}, {"subitem_subject": "NAG", "subitem_subject_scheme": "Other"}, {"subitem_subject": "β_2 ミクログロブリン", "subitem_subject_scheme": "Other"}, {"subitem_subject": "シスプラチン腎障害", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Cisplatin腎障害における尿中グアニジノ酢酸の動態", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Cisplatin腎障害における尿中グアニジノ酢酸の動態"}, {"subitem_title": "Cisplatin腎障害における尿中グアニジノ酢酸の動態", "subitem_title_language": "en"}]}, "item_type_id": "7", "owner": "1", "path": ["456", "1161"], "permalink_uri": "http://hdl.handle.net/10191/37460", "pubdate": {"attribute_name": "公開日", "attribute_value": "2016-02-03"}, "publish_date": "2016-02-03", "publish_status": "0", "recid": "20122", "relation": {}, "relation_version_is_last": true, "title": ["Cisplatin腎障害における尿中グアニジノ酢酸の動態"], "weko_shared_id": null}